

# **Porcine GM-CSF Antibody**

Recombinant Monoclonal Rabbit IgG Clone # 1202D Catalog Number: MAB7111


DESCRIPTION	
Species Reactivity	Porcine
Specificity	Detects porcine GM-CSF in direct ELISAs.
Source	Recombinant Monoclonal Rabbit IgG Clone # 1202D
Purification	Protein A or G purified from cell culture supernatant
Immunogen	E. coli-derived recombinant porcine GM-CSF Ala18-Lys144 Accession # Q29118
Endotoxin Level	<0.10 EU per 1 µg of the antibody by the LAL method.
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

#### **APPLICATIONS**

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Neutralization

Measured by its ability to neutralize GM-CSF-induced proliferation in the TF-1 human erythroleukemic cell line. Kitamura, T. et al. (1989) J. Cell Physiol. 140:323. The Neutralization Dose (ND<sub>50</sub>) is typically 0.02-0.1 μg/mL in the presence of 10 ng/mL Recombinant Porcine GM-CSF



GM-CSF and Neutralization by Porcine GM-CSF Antibody. Recombinant Porcine GM-CSF (Catalog # 711-PG) stimulates proliferation in the TF-1 human erythroleukemic cell line in a dose-dependent manner (orange line) as measured by Resazurin (Catalog # AR002). Proliferation elicited by Recombinant Porcine GM-CSF (10 ng/mL) is neutralized (green line) by increasing concentrations of Rabbit Anti-Porcine GM-CSF Monoclonal Antibody (Catalog # MAB7111). The ND<sub>50</sub> is typically 0.02-0.1 µg/mL.

Reconstitution	Reconstitute at 0.5 mg/mL in sterile PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
	12 months from date of receipt, -20 to -70 °C as supplied.
	<ul> <li>1 month, 2 to 8 °C under sterile conditions after reconstitution.</li> </ul>
	<ul> <li>6 months, -20 to -70 °C under sterile conditions after reconstitution.</li> </ul>

Rev. 2/7/2018 Page 1 of 2





# **Porcine GM-CSF Antibody**

Recombinant Monoclonal Rabbit IgG Clone # 1202D Catalog Number: MAB7111

#### BACKGROUND

GM-CSF was initially characterized as a factor that can support the *in vitro* colony formation of granulocyte-macrophage progenitors. It is also a growth factor for erythroid, megakaryocyte, and eosinophil progenitors. GM-CSF is produced by a number of different cell types (including T cells, B cells, macrophages, mast cells, endothelial cells, fibroblasts, and adipocytes) in response to cytokine or inflammatory stimuli. On mature hematopoietic cells, GM-CSF is a survival factor for and activates the effector functions of granulocytes, monocytes/macrophages, and eosinophils (1, 2). GM-CSF promotes a Th1 biased immune response, angiogenesis, allergic inflammation, and the development of autoimmunity (3-5). It shows clinical effectiveness in ameliorating chemotherapy-induced neutropenia, and GM-CSF transfected tumor cells are utilized as cancer vaccines (6, 7). The 22 kDa glycosylated GM-CSF, similar to IL-3 and IL-5, is a cytokine with a core of four bundled α-helices (8-10). Mature porcine GM-CSF shares 61%-72% amino acid sequence identity with canine, feline, human, and rat GM-CSF and 53% with mouse GM-CSF. GM-CSF exerts its biological effects through a heterodimeric receptor complex composed of GM-CSF Rα/CD116 and the signal transducing common β chain (CD131) which is also a component of the high-affinity receptors for IL-3 and IL-5 (11, 12). In addition, GM-CSF binds a naturally occurring soluble form of GM-CSF Rα (13). The activity of GM-CSF is species specific between human and mouse (14).

### References:

- 1. Martinez-Moczygemba, M. and D.P. Huston (2003) J. Allergy Clin. Immunol. 112:653.
- 2. Barreda, D.R. et al. (2004) Dev. Comp. Immunol. 28:509.
- 3. Eksioglu, E.A. et al. (2007) Exp. Hematol. 35:1163.
- 4. Cao, Y. (2007) J. Clin. Invest. 117:2362.
- 5. Fleetwood, A.J. et al. (2005) Crit. Rev. Immunol. 25:405.
- Heuser, M. et al. (2007) Semin. Hematol. 44:148.
- Hege, K.M. et al. (2006) Int. Rev. Immunol. 25:321.
- 8. Kaushansky, K. et al. (1992) Biochemistry 31:1881.
- 9. Diederichs, K. et al. (1991) Science 254:1779.
- 10. Inumaro, S. and H. Takamatsu (1995) Immunol. Cell Biol. 73:474.
- 11. Onetto-Pothier, N. et al. (1990) Blood 75:59.
- 12. Hayashida, K. et al. (1990) Proc. Natl. Acad. Sci. 87:9655.
- 13. Pelley, J.L. et al. (2007) Exp. Hematol. 35:1483.
- 14. Shanafelt, A.B. et al. (1991) J. Biol. Chem. 266:13804.